JP2024522065A - シロシビンの製剤 - Google Patents

シロシビンの製剤 Download PDF

Info

Publication number
JP2024522065A
JP2024522065A JP2023571283A JP2023571283A JP2024522065A JP 2024522065 A JP2024522065 A JP 2024522065A JP 2023571283 A JP2023571283 A JP 2023571283A JP 2023571283 A JP2023571283 A JP 2023571283A JP 2024522065 A JP2024522065 A JP 2024522065A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disorder
acid
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571283A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022243285A5 (https=
JP2024522065A5 (https=
Inventor
ニヴォロツキン，アレックス
パルフレイマン，マイケル
エル． エイヴリー，ケネス
エム． パサール，プラディプ
アイ． シュクル，モハメッド
Original Assignee
サイビン アイアールエル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイビン アイアールエル リミテッド filed Critical サイビン アイアールエル リミテッド
Publication of JP2024522065A publication Critical patent/JP2024522065A/ja
Publication of JPWO2022243285A5 publication Critical patent/JPWO2022243285A5/ja
Publication of JP2024522065A5 publication Critical patent/JP2024522065A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023571283A 2021-05-17 2022-05-17 シロシビンの製剤 Pending JP2024522065A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163189449P 2021-05-17 2021-05-17
US63/189,449 2021-05-17
PCT/EP2022/063269 WO2022243285A1 (en) 2021-05-17 2022-05-17 Formulations of psilocybin

Publications (3)

Publication Number Publication Date
JP2024522065A true JP2024522065A (ja) 2024-06-11
JPWO2022243285A5 JPWO2022243285A5 (https=) 2025-03-25
JP2024522065A5 JP2024522065A5 (https=) 2025-03-25

Family

ID=82019233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571283A Pending JP2024522065A (ja) 2021-05-17 2022-05-17 シロシビンの製剤

Country Status (7)

Country Link
US (1) US20240261306A1 (https=)
EP (1) EP4340809A1 (https=)
JP (1) JP2024522065A (https=)
KR (1) KR20240009433A (https=)
AU (1) AU2022277515B2 (https=)
CA (1) CA3216799A1 (https=)
WO (1) WO2022243285A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240074434A1 (en) * 2019-04-12 2024-03-07 Jeffrey Hanson Robbins Composition including effervescent agents, biostimulant, nutrient, and pesticide
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CA3247344A1 (en) * 2022-06-09 2023-12-14 Diamond Therapeutics Inc. AMORPHIC PSILOCYBIN (A-POLYMORPHIC)
US20250360148A1 (en) * 2022-06-22 2025-11-27 Cybin Irl Limited Solid dispersions of psilocybin
WO2024031152A1 (en) * 2022-08-12 2024-02-15 Woke Pharmaceuticals Pty Ltd Process for improving powder flow characteristics of a crystalline compound
EP4615444A1 (en) * 2022-11-07 2025-09-17 Natural Medtech Pty Ltd Tryptamine formulations and uses thereof
EP4720039A2 (en) * 2023-05-24 2026-04-08 Psilera Inc. Formulations containing tryptamine derivatives and uses thereof
WO2025080937A1 (en) * 2023-10-11 2025-04-17 University Of Padova Compositions with psilocybin and psilocin derivatives

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015738A1 (en) * 2008-01-23 2011-01-20 Ams Research Corporation Inflatable medical implant system
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
WO2020148442A1 (en) * 2019-01-18 2020-07-23 Merck Patent Gmbh Method for manufacturing a solid administration form and solid administration form
WO2020212952A1 (en) * 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
JP2020536960A (ja) * 2017-10-09 2020-12-17 コンパス パスファインダー リミテッド シロシビン、異なる多形形態、中間体、調合物の調製及びそれらの使用
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US11000534B1 (en) * 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015738A1 (en) * 2008-01-23 2011-01-20 Ams Research Corporation Inflatable medical implant system
JP2013103899A (ja) * 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
JP2020536960A (ja) * 2017-10-09 2020-12-17 コンパス パスファインダー リミテッド シロシビン、異なる多形形態、中間体、調合物の調製及びそれらの使用
WO2020148442A1 (en) * 2019-01-18 2020-07-23 Merck Patent Gmbh Method for manufacturing a solid administration form and solid administration form
WO2020212952A1 (en) * 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US11000534B1 (en) * 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROWN, R. T. ET AL.: "Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults", CLIN PHARMACOKINET, vol. 56, no. 12, JPN6026008972, 2017, pages 1543 - 1554, ISSN: 0005813251 *
DINIS-OLIVEIRA, R. J.: "Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance", DRUG METABOLISM REVIEWS, vol. 49, no. 1, JPN6026008973, 2017, pages 84 - 91, ISSN: 0005813252 *
HARBESON, S.AND TUNG, R.: "Deuterium Medicinal Chemistry: A New Approach to Drug Discoveryand Development", MEDCHEM NEWS, JPN6023040163, 2014, pages 8 - 22, ISSN: 0005813250 *
MICHAERL, W. J.: "Psilocybin Revisited: The Science Behind the Drug and Its Surprising Therapeutic Potentia", PSYCHIATRIC TIMES, vol. 38, no. 3, JPN6026008975, 20 March 2021 (2021-03-20), pages 39 - 43, ISSN: 0005813254 *
TUNG, R.: "The Development of Deuterium-Containing Drugs", INNOVATIONS IN PHARMACEUTICAL TECHNOLOGY, vol. 32, JPN6023040164, 2010, pages 24 - 28, ISSN: 0005813249 *
紺野 肇: "固体分散体中薬物の安定化に及ぼすポリマーの効果", 薬剤学, vol. 71, no. 2, JPN6026008974, 2011, pages 109 - 113, ISSN: 0005813253 *

Also Published As

Publication number Publication date
KR20240009433A (ko) 2024-01-22
AU2022277515A1 (en) 2023-10-19
EP4340809A1 (en) 2024-03-27
US20240261306A1 (en) 2024-08-08
CA3216799A1 (en) 2022-11-24
AU2022277515B2 (en) 2026-01-15
WO2022243285A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
JP2024522065A (ja) シロシビンの製剤
US20250213527A1 (en) Formulations of psilocybin analogs and methods of use
TWI522100B (zh) 含有納布啡（ｎａｌｂｕｐｈｉｎｅ）之藥學組成物及其用途
JP2012254993A (ja) バルデナフィルを含有する制御放出製剤
WO2022195011A1 (en) Psilocybin analogs, salts, compositions, and methods of use
JP2024533291A (ja) 併用薬物療法
ZA200703866B (en) Pharmaceutical formulation containing a release rate controlling compositions
JP2025506504A (ja) 治療用フェネチルアミン組成物及び使用方法
EP3165220A1 (en) Pharmaceutical composition containing an anti-nucleating agent
JP2025502208A (ja) トリプタミン組成物および方法
JP2007530692A (ja) ６−メルカプトプリンの改良された製剤
KR20250053871A (ko) 트립타민 화합물, 조성물, 및 사용 방법
KR101068475B1 (ko) 실로스타졸을 포함하는 서방성 제제 및 이의 제조방법
AU2026202771A1 (en) Formulations of psilocybin
EP4260860A1 (en) Intracellular atp enhancer
US20240174607A1 (en) Psilocybin analogs, salts, compositions, and methods of use
CN118234708A (zh) 裸头草碱类似物的调配物和使用方法
JP2026513655A (ja) フェネチルアミン化合物、組成物、及び使用方法
CN118632835A (zh) 色胺组合物和方法
HK40099695A (zh) 包含(4s)-2⁴-氯-4-乙基-7³-氟-3⁵-甲氧基-3²，5-二氧代-1⁴-(三氟甲基)-3²h-6-氮杂-3(4，1)-吡啶-1(1)-[1，2，3]三唑-2(1，2)，7(1)-二苯七蕃-7⁴-甲酰胺的药物剂型

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310